ImmunityBio
  • Our Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Unique Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Therapies
    • Bladder Cancer
    • Glioblastoma
    • Lynch Syndrome
    • Non-Small Cell Lung Cancer
    • Pancreatic Cancer
    • COVID-19
    • HIV
  • Our Company
    • About Us
    • Investors
    • News
    • Contact
  • Careers
  • Get Started
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
Select Page

Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.

Feb 12, 2013 | Uncategorized

Recent Posts

  • ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
  • First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
  • FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
  • ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
  • Piper Sandler Annual Healthcare Conference

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  Twitter
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2023 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘haNK’, ‘taNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, ImmunityBio, Inc.

Anktiva is a registered trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap